Deferasirox

ইঙ্গিত

Deferasirox is used to treat chronic iron overload caused by repeated blood transfusions in adults and children aged 2 years and older who have thalassaemia, sickle cell disease or myelodysplastic syndrome. It is also used to treat chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassaemia syndromes.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Deferasirox is taken by mouth and works as an iron chelator with high selectivity for iron. It is a tridentate ligand, meaning it binds iron in a 2:1 ratio with strong affinity. The medicine helps the body get rid of excess iron mainly through the stool. Deferasirox has only a weak affinity for zinc and copper, so it does not lead to persistently low levels of these metals in the blood. In a metabolic study looking at iron balance in adult thalassaemia patients with iron overload, daily doses of 10, 20, and 40 mg/kg led to a mean net iron excretion of 0.119, 0.329, and 0.445 mg per kg of body weight per day, respectively.

Pregnancy & Breastfeeding

Pregnancy Category C. Deferasirox has not been studied in adequate, well-controlled trials involving pregnant women. In animal studies, giving Deferasirox during pregnancy and breastfeeding reduced offspring survival and increased kidney abnormalities in male offspring, at doses lower than those typically used in humans. For this reason, Deferasirox should be used in pregnancy only if the expected benefit to the mother outweighs the possible risk to the unborn baby. Whether Deferasirox passes into human breast milk is not currently known.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Dosage Deferasirox should be started after the patient has received approximately 20 units (about 100 ml/kg) of packed red blood cells, or when there is evidence of chronic iron overload (for example, a serum ferritin level above 1,000 microgram/L). The recommended starting dose is 20-40 mg/kg body weight once daily, taken on an empty stomach, preferably half an hour before breakfast. How to take the tablets: Disperse the tablets by stirring them in a glass (100 to 200 ml) of water, apple juice or orange juice until a fine suspension forms. After swallowing the suspension, re-suspend any residue in a small amount of water or juice and swallow that as well. The tablets must not be chewed or swallowed whole. Dispersing them in carbonated drinks or milk is not recommended, because carbonated drinks cause foaming and milk disperses the tablets slowly. Monitoring and dose adjustment: Serum ferritin should be checked every month, and the dose adjusted every 3 to 6 months according to the trend in serum ferritin. If iron overload is not adequately controlled, doses of up to 40 mg/kg may be considered. Once serum ferritin is under control, dose reductions in steps of 5 to 10 mg/kg should be considered in order to keep serum ferritin at around 500 microgram/L. Treatment may be interrupted if sustained control has been achieved.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.

প্রধান পারস্পরিক ক্রিয়া

Checker →

Suggest a correction